Biohaven Pharmaceutical Holding Co Ltd (BHVN)
$11.09
$-0.03
(-0.27%)
As on 09-Jun-2026 16:00EDT
Market cap
$1,626 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
13.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-3.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.2
-
Debt to Equity
1.9
-
Book Value
$--
-
EPS
$-5.7
-
Face value
--
-
Shares outstanding
150,560,990
10 Years Aggregate
CFO
$-1,556.79 Mln
EBITDA
$-2,233.19 Mln
Net Profit
$-2,283.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Co (BHVN)
| -1.8 | 12.5 | 11.8 | -34.9 | -21.7 | -35.0 | -- |
|
BSE Sensex*
| -12.3 | -3.9 | -4.2 | -9.9 | 5.9 | 7.4 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Co (BHVN)
| -69.8 | 208.4 | -89.9 | 60.8 | 57.4 | 47.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Biohaven Pharmaceutical Holding Co (BHVN)
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to... treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Read more
-
Chairman & CEO
Dr. Vladimir Coric M.D.
-
Chairman & CEO
Dr. Vladimir Coric M.D.
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biohaven Pharmaceutical Holding Co (BHVN)
What is the current share price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Today?
The share price of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is $11.09 (NYSE) as of 09-Jun-2026 16:00 EDT. Biohaven Pharmaceutical Holding Co Ltd (BHVN) has given a return of -21.73% in the last 3 years.
What is the current PB & PE ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN)?
Since, TTM earnings of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.84
|
26.06
|
|
2024
|
-4.46
|
8.91
|
|
2023
|
-8.38
|
7.99
|
|
2022
|
-1.48
|
1.57
|
|
2021
|
-25.38
|
57.29
|
What is the 52 Week High and Low of Biohaven Pharmaceutical Holding Co Ltd (BHVN)?
The 52-week high and low of Biohaven Pharmaceutical Holding Co Ltd (BHVN) are Rs 18.57 and Rs 7.48 as of 10-Jun-2026.
What is the market cap of Biohaven Pharmaceutical Holding Co Ltd (BHVN)?
Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a market capitalisation of $ 1,626 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biohaven Pharmaceutical Holding Co Ltd (BHVN)?
Before investing in Biohaven Pharmaceutical Holding Co Ltd (BHVN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.